Labège, 22 January 2019. We are pleased to announce that Antabio’s CEO Marc Lemonnier has been appointed as a new member of the Scientific Advisory Board (SAB) of JPIAMR.
The Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) is a global collaborative platform, with 27 nations working to curb antibiotic resistance (AMR) with a One Health approach. JPIAMR jointly funds and coordinates national investments to support transnational research and activities within the six priority areas of the shared Strategic Research Agenda. To date, JPIAMR has funded 70 projects and 340 research groups, with a total of over 67 M Euro in funding. By mobilising existing and new resources, the initiative creates a greater critical mass and attracts new researchers into the AMR field.
At the JPIAMR SAB, Marc Lemonnier will contribute to delivering strategic advice on scientific issues including collaborative actions. The SAB is made up of experts in the field, whose academic and/or social standing makes them uniquely qualified to assess and appreciate endeavours and developments in the global fight against antimicrobial resistance.
For more information visit the JPIAMR website: https://www.jpiamr.eu/